Landmark Medicines advances nasal GLP-1 platform
UK-based Landmark Medicines has announced plans to take its proprietary intranasal delivery platform into a human volunteer study, with GLP-1 receptor agonists as the first application.
The company said that it is evaluating candidate molecules, including semaglutide, before making a final selection.
The platform is designed to be formulation-agnostic and is the subject of multiple patent filings.
The first study will focus on pharmacokinetics, systemic bioavailability, dose requirements, safety and tolerability, with this data determining whether nasal administration can offer meaningful advantages compared with existing approaches.
Landmark also intends to investigate a potential nose-to-brain pathway separately.